EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice

Lucia Tricarico iD, Michele Correale iD, Ester Maria Lucia Bevere, Natale Daniele Brunetti, Massimo Iacoviello iD

Reviews in Cardiovascular Medicine · 29.08.2025 · 26 (8)

DOI: 10.31083/rcm39886 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 29.08.2025. Verfasst von Lucia Tricarico und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortality. Despite advancements in guideline-directed medical therapy (GDMT), many patients continue to be at risk for worsening heart failure (WHF). Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator that targets the impaired nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) pathway. Thus, by improving vascular and myocardial function, vericiguat offers a promising therapeutic option for patients with HFrEF who remain symptomatic despite receiving optimal medical treatment. This review explores the pathophysiological rationale, mechanism of action, and clinical evidence supporting the use of vericiguat. We analyze data from key randomized controlled trials (RCTs), such as SOCRATES-REDUCED and VICTORIA, as well as meta-analyses, to assess the efficacy and safety of using vericiguat in HFrEF. Additionally, we review real-world studies to evaluate the applicability of vericiguat in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

heart failurenitric oxidesoluble guanylate cyclasevericiguatworsening heart failure

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.
  • Cardiothoracic Department, Ospedali Riuniti University Hospital, 71122 Foggia, Italy.

ORCID-Profile: Lucia Tricarico, Michele Correale, Massimo Iacoviello

Zitieren

APA

Tricarico, L., Correale, M., Bevere, E. M. L., Daniele Brunetti, N., & Iacoviello, M. (2025). The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice. Reviews in Cardiovascular Medicine, 26(8). https://doi.org/10.31083/rcm39886

Vancouver

Tricarico L, Correale M, Bevere EML, Daniele Brunetti N, Iacoviello M. The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice. Reviews in Cardiovascular Medicine. 2025;26(8). doi:10.31083/rcm39886

BibTeX
@article{Tricarico2025,
  author = {Tricarico, Lucia and Correale, Michele and Bevere, Ester Maria Lucia and Daniele Brunetti, Natale and Iacoviello, Massimo},
  title = {The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2025},
  volume = {26},
  number = {8},
  doi = {10.31083/rcm39886}
}
Kostenlos starten →